Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8XK6L)

• DTT Name: Quinone reductase 1 (NQO1) DTT Info
• Gene Name: NQO1

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ 761	DMH5CAL	Pancreatic cancer	2C10	Phase 2	[1]
BioE-743	DM7PT8R	Leigh syndrome	5C53.24	Phase 2	[2]
Coenzyme Q10 analog	DMO0VGH	Huntington disease	8A01.10	Phase 2	[3]

28 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one	DMV7IWE	Discovery agent	N.A.	Investigative	[4]
3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one	DM9BYVL	Discovery agent	N.A.	Investigative	[4]
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one	DMA5EHC	Discovery agent	N.A.	Investigative	[4]
3-Benzyl-4-hydroxy-2H-chromen-2-one	DM3BFX0	Discovery agent	N.A.	Investigative	[4]
3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one	DML0ME9	Discovery agent	N.A.	Investigative	[4]
4-amino-2H-chromen-2-one	DM3MUF1	Discovery agent	N.A.	Investigative	[5]
4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one	DMY3OHK	Discovery agent	N.A.	Investigative	[4]
4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one	DMM3QPL	Discovery agent	N.A.	Investigative	[4]
Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]	DMVRXH3	Discovery agent	N.A.	Investigative	[6]
Duroquinone	DML7YPS	Discovery agent	N.A.	Investigative	[6]
ES-936	DMIVZ3W	Discovery agent	N.A.	Investigative	[7]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate	DMJQTIK	Discovery agent	N.A.	Investigative	[4]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[6]
NSC-106080	DMR6P9S	Discovery agent	N.A.	Investigative	[8]
NSC-106547	DMR2DTI	Discovery agent	N.A.	Investigative	[9]
NSC-2113	DMOGV9F	Discovery agent	N.A.	Investigative	[9]
NSC-224124	DMM9PDR	Discovery agent	N.A.	Investigative	[9]
NSC-275420	DMV2D8F	Discovery agent	N.A.	Investigative	[9]
NSC-316158	DMTPRXI	Discovery agent	N.A.	Investigative	[9]
NSC-339580	DMK0H2P	Discovery agent	N.A.	Investigative	[9]
NSC-339583	DMITE1A	Discovery agent	N.A.	Investigative	[9]
NSC-354279	DMVL51I	Discovery agent	N.A.	Investigative	[9]
NSC-621351	DMFXEIK	Discovery agent	N.A.	Investigative	[8]
NSC-645808	DMMBAR3	Discovery agent	N.A.	Investigative	[9]
NSC-645827	DMNJLW2	Discovery agent	N.A.	Investigative	[9]
NSC-65069	DMFEGYB	Discovery agent	N.A.	Investigative	[8]
NSC-73410	DMX0VQN	Discovery agent	N.A.	Investigative	[9]
NSC-99528	DMXZAIG	Discovery agent	N.A.	Investigative	[8]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
• [4] Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
• [5] Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human panc... J Med Chem. 2007 Dec 13;50(25):6316-25.
• [6] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [7] Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) ... J Med Chem. 2007 Nov 15;50(23):5780-9.
• [8] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [9] In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.